| 摘要 |
The present invention found the interaction of CREBL1 and HNF-4alpha with HtrA2 and revealed for the first time that CREBL1, ATF6, and HNF-4alpha are degraded by active HtrA2. In addition, the present invention provides a means for inhibiting the degradation of at least one of CREBL1, ATF6, and HNF-4alpha, comprising inhibiting the function of HtrA2; a means for preventing and/or treating diabetes, comprising inhibiting the degradation by HtrA2 of at least one of CREBL1, ATF6, and HNF-4alpha; a means for preventing cell death (for example, pancreatic beta cell death), comprising inhibiting the degradation by HtrA2 of CREBL1 and/or ATF6; a means for preventing and/or treating type 2 diabetes, comprising inhibiting the degradation by HtrA2 of HNF-4alpha; and a reagent kit.
|
